Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer
Aime T. Franco, … , Theodore W. Laetsch, Andrew J. Bauer
Aime T. Franco, … , Theodore W. Laetsch, Andrew J. Bauer
Published September 15, 2021
Citation Information: J Clin Invest. 2021;131(18):e152696. https://doi.org/10.1172/JCI152696.
View: Text | PDF
Commentary Article has an altmetric score of 2

Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer

  • Text
  • PDF
Abstract

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer in the pediatric population and represents the second most common malignancy in adolescent females. Historically, PTC has been classified on the basis of histology, however, accumulating data indicate that molecular subtyping based on somatic oncogenic alterations along with gene expression profiling can better predict clinical behavior and may provide opportunities to incorporate oncogene-specific inhibitory therapy to improve the response to radioactive iodine (RAI). In this issue of the JCI, Y.A. Lee, H. Lee, and colleagues showed that oncogenic fusions were more commonly associated with invasive disease, increased expression of MAPK signaling pathway genes (ERK score), and decreased expression of the sodium-iodine symporter, which was restored by RET- and NTRK-inhibitory therapy. These findings lend credence to the idea of reclassifying pediatric thyroid cancers using a three-tiered system, rather than the two-tiered adult system, and open avenues for the treatment of progressive, RAI-refractory PTC in patients.

Authors

Aime T. Franco, Julio C. Ricarte-Filho, Theodore W. Laetsch, Andrew J. Bauer

×

Total citations by year

Year: 2025 2023 Total
Citations: 1 4 5
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (5)

Title and authors Publication Year
Recent Advances in Diagnostics and Therapeutics for Paediatric Thyroid Cancer
Vanderniet JA, Fuentes\u2010Bolanos NA, Cho YH, Chung DK, Sandler G, Moghimi A, Padhye B, Tucker K, Anazodo A, Benitez\u2010Aguirre PZ
Journal of Paediatrics and Child Health 2025
The Double-Edged Proteins in Cancer Proteomes and the Generation of Induced Tumor-Suppressing Cells (iTSCs)
Li K, Huo Q, Li BY, Yokota H
Proteomes 2023
Targeting Tumor Microenvironment Akt Signaling Represents a Potential Therapeutic Strategy for Aggressive Thyroid Cancer
Mirshahidi S, Yuan IJ, Simental A, Lee SC, Peterson NR, Andrade Filho PA, Murry T, Duerksen-Hughes P, Yuan X
International journal of molecular sciences 2023
Advances in transcriptomics and proteomics in differentiated thyroid cancer: An updated perspective (Review)
Yang S, Zhu G, He R, Fang D, Feng J
Oncology Letters 2023
Pulmonary injury after radioactive iodine therapy in pediatric papillary thyroid cancer: a case report
Halada S, Dobkin SL, Baran JA, Sisko L, Robbins SL, Rapp JB, Young LR, Bauer AJ
Hormone Research in Paediatrics 2023

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 2 X users
30 readers on Mendeley
See more details